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Background and aims: Polycystic ovary syndrome (PCOS) is a common endocrine disorder, presenting polygenic
traits as well as determined by environmental factors. Given the overlap between PCOS and obesity, we assessed
the frequencies of SNPs rs9939609 and rs8050136 in intron 1 of the FTO gene and their haplotypes in women
with PCOS and healthy controls with regular cycles from Southern Brazil and investigated their relationship
with metabolic traits and endocrine parameters.
Subjects and methods: The sample comprised 298 women (199 with PCOS and 99 non-hirsute women with
regular ovulatory cycles). FTO genotyping was done by real-time PCR. Haplotypes were constructed from the
combination of both polymorphisms. Frequencies were inferred using PHASE 2.1.1 software.
Results: The distribution of rs9939609 (PCOS: 32.6% TT, 45.9% TA, 21.5% AA; controls: 33.3% TT, 49.0% TA,
17.7% AA) and rs8050136 (PCOS: 21.7% AA, 43.3% AC, 35.0% CC; controls: 14.9% AA, 48.9% AC, 36.2% CC)was sim-
ilar between groups. The mean age of participants was 22.7 ± 7.1 years. Women with PCOS had signiﬁcantly
higher BMI, waist circumference, total testosterone, and FAI vs. controls. In the PCOS group, no differences
between genotypes and haplotypes were found for clinical variables. The presence of at least one risk allele for
polymorphisms rs9939609 and rs8050136 was associated with higher fasting glucose levels.
Conclusion: Our ﬁndings indicate that neither the FTO rs9939609 and rs8050136 polymorphisms nor its haplo-
types are related to PCOS, but suggest an association between the presence of risk alleles of SNPs rs9939609
and rs8050136 in FTO and glucose levels in women from Southern Brazil.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous disease char-
acterized mainly by chronic anovulation and manifestations of
hyperandrogenism. Using the Rotterdam consensus diagnostic criteria,
PCOS affects up to 18% (March et al., 2010). Obesity is one of the most
prevalent features of PCOS (Graff et al., 2013; Peppard et al., 2001;
ESHRE/ASRM, 2004; Apridonidze et al., 2005). A recent meta-analysis
showed thatwomenwith PCOS had increased prevalence of overweight
as well as obesity (Lim et al., 2012), and abdominal obesity is found in
most women with the condition, in association with metabolic distur-
bances such as insulin resistance (IR) (Apridonidze et al., 2005). Indeed,
the metabolic syndrome (MetS), deﬁned as a cluster of central obesity,
dyslipidemia, hypertension, and glucose intolerance, is found in 30–e;DM2,diabetesmellitustype2;
ted gene; Ht, haplotype; HDL-c,
rg equilibrium;MetS,metabolic
e; SNP, single nucleotide poly-
, Hospital de Clínicas de Porto
-003, Brazil.40% of women with PCOS, and 25–35% of obese women with PCOS are
diagnosed with impaired glucose tolerance or diabetes around the age
of 30. This prevalence is nearly twofold higher than that for age-
adjusted women in the general population (Gambineri et al., 2002;
Apridonidze et al., 2005; Carmina et al., 2006;Wild et al., 2010). In gen-
eral, womenwith PCOShave 3–7 timesmore risk of developingdiabetes
mellitus type 2 (DM2) compared with the general population
(Ehrmann et al., 1999; Legro et al., 1999).
Individual susceptibility to PCOS is determined by genetic and envi-
ronmental factors. Among several candidate genes for obesity, the fat
mass and obesity associated gene (FTO) has been recently identiﬁed.
FTO is located on chromosome 16q12.2 (Frayling et al., 2007) and, sta-
tistically, remains the candidate genewith the largest effect size on obe-
sity. The protein it encodes is a member of the nonheme dioxygenase
(Fe(II)- and 2-oxoglutarate-dependent dioxygenases) superfamily
(Gerken et al., 2007; Sanchez-Pulido and Andrade-Navarro, 2007), and
is involved in various cellular processes, including DNA repair, fatty
acid metabolism, and posttranslational modiﬁcations. However, to
date, its link to body weight regulation remains unclear.
Thus far, studies have shown controversial results. Some investiga-
tions demonstrated an association with PCOS (Attaoua et al., 2008;
Barber et al., 2008; Yan et al., 2009), whereas others found no such
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due to factors such as ethnicity or whether there was adjustment for
body mass index (BMI) in each individual study.
A recent meta-analysis showed no association between FTO gene
polymorphisms and PCOS susceptibility. On subgroup analysis, the as-
sociationwas signiﬁcant in East Asians but not in Caucasians, suggesting
an effect of ethnicity on the association. Further studies are required to
assess the real impact of polymorphisms in the FTO gene on PCOS in
other populations (Cai et al., 2014).
Within this context, the aim of the present study was to assess
whether the prevalence of SNPs rs9939609 and rs8050136 in intron 1
of the FTO gene and their haplotypes differs between women with
PCOS and healthy controls with regular cycles from Southern Brazil,
and to investigate the relationship of these genetic factors with meta-
bolic traits and endocrine parameters.
2. Material and methods
2.1. Patients
The study population includedwomen of reproductive age recruited
by advertisement in the local media between 2009 and 2013 and who
met the inclusion criteria. The advertisement called for volunteers
with hirsutism and irregular menses and also for volunteers without
hirsutism and with regular menses (to be enrolled as controls). The
enrollment was planned to include PCOS and controls participants in a
proportion of 2:1.
The study population comprised 298 women: 199 patients with
PCOS and 99 non-hirsute women with regular, ovulatory cycles (luteal
phase progesterone N3.8 ng/ml). The mean age of participants
was 22.7± 7.1 years. All participants had attended a university hospital
in Southern Brazil (Hospital de Clínicas de Porto Alegre, state of Rio
Grande do Sul). PCOS was diagnosed according to the Rotterdam
criteria as the presence of two out of three of the following signs: 1) Ol-
igomenorrhoea and/or chronic anovulation (≤9 cycles/year and/or
luteal phase progesterone b 3.8 ng/mL), 2) clinical and/or biochemical
hyperandrogenism, and 3) polycystic ovaries (PCO) on ultrasound ex-
amination. Diagnosis of PCOS also relied on exclusion of other
hyperandrogenic disorders (ESHRE/ASRM, 2004). None of the PCOS or
control participants had received any drugs known to interfere with
hormone levels (such as oral contraceptive pills, antiandrogens,metfor-
min, ﬁbrates, or statins) for at least 3 months before the study. The
exclusion criteria were pregnancy, liver disease, or kidney disease.
2.2. Study protocol
Anthropometric measurements included body mass index (BMI)
(currentweight in kg divided by the height inm squared) andwaist cir-
cumference (measured at the midpoint between the lower rib margin
and the iliac crest) (Toscani et al., 2007). Blood pressure was measured
after a 10-minute rest, with the patient seated, with both feet on the
ﬂoor, and the arm supported at heart level. Two measurements were
obtained 10 min apart using an Omron HEM-742INT automatic blood
pressure monitor (Rio de Janeiro, Brazil) with the correct cuff size for
the arm diameter. MetS and the cutoffs for its isolated components
were deﬁned in accordance with the Joint Scientiﬁc Statement (Alberti
et al., 2009). A Z score was calculated for metabolic syndrome
([value−mean] / SD) to deﬁne metabolic risk clustering on a continu-
ous scale. The Z scores were multiplied by−1 if necessary to indicate
higher metabolic risk increasing value. A lower risk score is indicative
of a better metabolic proﬁle.
Approval for this study was obtained from the Institutional Review
Board and the local Research Ethics Committee, functioning according
to the 3rd edition of the Guidelines on the Practice of Ethical Commit-
tees in Medical Research issued by the Royal College of Physicians of
London, andwritten informed consentwas obtained fromevery subject.2.3. Laboratory measurements
All samples were obtained between the 2nd and 10th days of the
menstrual cycle, or on any day if the patient was amenorrheic, between
8:00 and 10:00 am, after a 12-h overnight fast. Oral glucose tolerance
test (oGTT) was also tested. Blood samples were drawn from an
antecubital vein for the determination of hormonal levels. Glucose
levels were determined by enzymatic colorimetric methods (Bayer
1650 Advia System). Hormonal measurements were performed using
commercial kits, as previously described (Nacul et al., 2007; Toscani
et al., 2007;Wiltgen et al., 2009). The free androgen index was calculat-
ed as testosterone (nmol/L) / SHBG (nmol/L) × 100.2.4. Genotyping
In addition to serum samples, whole blood samples were collected
from all participants. Genomic DNA was extracted from peripheral leu-
kocytes as reported elsewhere (Ramos et al., 2013). The DNA samples
were diluted to 2 ng/mL and genotyped for SNP rs9939609 T N A and
rs8050136 A N C of the FTO gene by real-time polymerase chain reaction
(7500 Fast Real-Time Polymerase Chain Reaction System, Applied
Biosystems, CA, USA), using the allelic discrimination assay with
TaqMan MGB primers and probes (Applied Biosystems, CA, USA).
TaqMan Master mix (2.5 μL), TaqMAn assay (0.25 μL), and H2O
(1.25 μL) were added for a ﬁnal volume of 4 μL per sample, and 1 μL of
DNA was added for a total reaction volume of 5 μL. Reaction conditions
for the SNP rs9939609 were: 10 min at 95 °C after 50 cycles of
denaturation at 95 °C (15 s) and annealing at 61 °C (1 min). Endpoint
ﬂuorescent readings were performed in the 7500 Fast System Sequence
Detection Software version 1.4 environment. The internal quality of
genotype data was assessed by typing 20% of blinded samples in
duplicate.
Haplotypes were constructed from the combination of the two FTO
polymorphisms (rs9939609 and rs8050136), and their frequencies
were inferred using the PHASE 2.1.1 program (Stephens et al., 2001).
The ﬁrst letter of each haplotype refers to the rs8050136polymorphism,
and the second to the rs9939609 polymorphism.2.5. Statistical analysis
Results are presented as mean ± standard deviation for normally
distributed variables or as median (interquartile range) for variables
with a non-Gaussian distribution. The Kolmogorov–Smirnov test and
descriptive statistics were used to evaluate the distribution of data.
Non-Gaussian variables were log-transformed for statistical analysis
with an independent Student t test and one-way ANOVA and reported
as back-transformed into their original units. Binary logistic regression
analyses were performed to examine the ORs of PCOS (dependent var-
iable) with genotype. The chi-square test was used to compare categor-
ical variables, and to assess deviation of the genotype frequencies from
Hardy–Weinberg equilibrium. Previous studies have shown that the
rs8050136 “A” allele is in strong linkage disequilibrium with the
rs9939609 “A” allele (Frayling et al., 2007; Hotta et al., 2008; Ramos
et al., 2011). For each studied polymorphism, patients were divided
into two groups: one combined heterozygous and risk homozygous
subjects into a single group and the second comprised non-risk homo-
zygous subjects. For rs9939609, we combined TA (heterozygous) and
AA (polymorphic homozygous) as one group andwild type TT (wild ho-
mozygous) as the second group,with a dominantmodel; for rs8050136,
we combined AC (heterozygous) and AA (wild homozygous) as one
group and CC (polymorphic homozygous) as the second group, with a
recessive model. All analyses were carried out in SPSS version 18.0
(SPSS, Inc., Chicago, IL, USA). Findings were considered signiﬁcant
at p b 0.05.
Table 2
Association between FTO gene variants and PCOS susceptibility.












OR 1.07 (0.63–1.81) 0.78
able 3
linical characteristics of the PCOS group according to different genotypes for SNP
s9939609, rs8050136 and haplotypes.
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Participants were mostly Caucasian (93.9%), with the remaining
participants having mixed African and European ancestry. The clinical
characteristics of the sample are shown in Table 1. As expected,
women with PCOS had signiﬁcantly higher BMI, waist circumference,
total testosterone and FAI (p = 0.001), as well as a higher frequency
of blood pressure (BP) ≥ 130/85 mm Hg, HDL-C b 50 mg/dL, triglycer-
ides ≥ 150 mg/dL, waist circumference N 88 cm, and MetS when
compared with the control group (p ≤ 0.05; Table 1).
The genotypes of the entire sample and its subgroups were in
Hardy–Weinberg equilibrium.Most of the samples (96.9% in the control
group and 91% in the PCOS group) were successfully genotyped. Geno-
type frequencies for rs9939609 in the FTO gene were as follows: 33.3%
TT, 49% TA, and 17.7% AA for controls and 32.6% TT, 45.9% TA, and
21.5% AA for the PCOS group. Genotype frequencies for rs8050136
were as follows: 14.9% AA, 48.9% AC, and 36.2% CC for controls and
21.7% AA, 43.3% AC, and 35% CC for PCOS subjects. Six haplotypes
were inferred in this sample (Ht1: CTCT, Ht2: CTCA, Ht3: CTAA, Ht4:
CAAA, Ht5: ATAA, Ht6: AAAA). Haplotype frequencies were 33.7% for
Ht1, 50.0% for Ht2/Ht3/Ht4/Ht5, and 16.3% for Ht6 in the control
group, versus 32.1% for Ht1, 48.4% for Ht2/Ht3/Ht4/Ht5, and 19.6% for
Ht6 in the PCOS group.
Logistic regression analysis demonstrated that SNPs rs9939609 and
rs8050136 and their haplotypes were not associated with an increased
risk of PCOS (ORs 1.03 (0.61–1.74), 1.05 (0.62–1.77) and 1.07 (0.63–
1.81), respectively; all p N 0.05, Table 2). Excluding non-Caucasian par-
ticipants do not change these results.
No interaction between cases and controls in the studied vari-
ables was observed among genotypes. Therefore, subsequent analy-
ses were conducted speciﬁcally on the PCOS group. Table 3 shows
BMI and biochemical characteristics according to the different SNPs
and haplotypes in PCOS subjects. BMI, glucose at 120 min, and
hormone levels (total testosterone and FAI) were similar between
genotypes, as were the frequencies of MetS and the metabolic syn-
drome Z score. In turn, individuals with at least one risk allele, TA
(heterozygous) and AA (polymorphic homozygous) genotypes, had
signiﬁcantly higher fasting glucose levels compared with individuals
presenting the wild TT genotype for SNP rs9939609 (TA/AA: 91.5 ±
18.4 vs. TT: 85.8 ± 11.5, p = 0.03). For SNP rs8050136, women
with the wild AA genotype and heterozygous AC also exhibited
higher fasting glucose levels (AA/AC: 91.7 ± 18.7 vs. CC: 86.5 ±
10.9, p = 0.04), while haplotypes presented a trend toward higher
fasting glucose (Ht2/Ht3/Ht4/Ht5/Ht6: 91.0 ± 18.5 vs. 86.4 ± 11.0 Ht1,
p = 0.08) (Fig. 1).Table 1
Clinical and biochemical proﬁle of the sample.
Variable PCOS (n = 199) Controls (n = 99) p-Value
BMI (kg/m2) 29.6 ± 6.4 27.0 ± 6.0 0.001
Waist circumference (cm) 89.2 ± 15.0 78.1 ± 11.5 0.001
Fasting glucose (mg/dL) 88.8 ± 12.2 88.4 ± 7.5 0.78
Glucose at 120 min (mg/dL) 113.6 ± 40.1 95.1 ± 21.2 0.001
Total testosterone (nmol/L) 0.9 ± 0.4 0.5 ± 0.1 0.001
FAI 3.40 (1.95–5.95) 1.25 (0.93–2.02) 0.001
Glucose ≥ 100 mg/dL (%) 19 (9.7%) 6 (7.7%) 0.60
BP ≥ 130/85 mm Hg (%) 68 (35.1%) 6 (7.1%) 0.005
HDL-C b 50 mg/dL (%) 112 (56.6%) 35 (40.7%) 0.014
Triglycerides ≥ 150 mg/dL (%) 35 (17.8%) 4 (4.7%) 0.003
Waist N 88 cm (%) 91 (49.2%) 12 (16.2%) 0.001
Metabolic syndrome 49 (24.6%) 2 (2.4%) 0.001
Metabolic syndrome (Z score) 0.75 ± 3.3 −1.2 ± 2.1 0.001
Data are expressed as mean ± SD or median (interquartile range) (Student t test). Total
testosterone reference range (female): 0.2–0.8 ng/mL; metabolic syndrome and its isolat-
ed components are presented as number of positive cases and percentage. BMI, bodymass
index; FAI, free androgen index; BP, blood pressure.4. Discussion
The present study suggests that the FTO gene polymorphisms
rs9939609 and rs8050136, as well as haplotypes, are not associated
with risk of PCOS. This is the ﬁrst study to evaluate such an associa-
tion in a Southern Brazilian population. Previous studies with PCOS
populations did not show conclusive results; three demonstrated
that variation within the FTO gene is signiﬁcantly associated with
PCOS in UK, Chinese, and Korean populations, but these associations
were attenuated and no longer signiﬁcant after adjusting for age and
BMI (Barber et al., 2008; Yan et al., 2009; Song do et al., 2014). Other
studies found no association with PCOS and the FTO gene, but have
found an association between PCOS and metabolic traits such as
BMI, body weight, and fat mass (Attaoua et al., 2008; Tan et al.,
2010; Wehr et al., 2010; Kim et al., 2014). These results are corrobo-
rated by a recent meta-analysis, which demonstrated that the
rs9939609 polymorphism (or its proxy) was not related to PCOS sus-
ceptibility after adjustment for BMI (Cai et al., 2014). This meta-
analysis suggested there might be a direct association between FTOata are expressed as mean ± SD values or median (interquartile range) (one-way
NOVA or Student t test); BMI, body mass index; FAI, free androgen index; OGTT, glucose
lerance test; TT, total testosterone; MetS, metabolic syndrome. a Between carriers of TT
s TA vs AA genotype for rs9939609; AA vs AC vs CC for rs8050136; and Ht1 vs Ht2/Ht3/
t4/Ht5 vs Ht6 for haplotypes. b Between carriers of TT vs TA/AA genotype for rs9939609;









Fig. 1. Associations of SNP rs9939609 (A), SNP rs8050136 (B) and haplotypes (C) with glucose. (Student's t-test). A. p = 0.03; B. p = 0.04; C. p = 0.08.
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the association was signiﬁcant after adjusting for BMI (Cai et al.,
2014). No studies are available concerning polymorphisms in the
FTO gene and PCOS in Latin American populations.
Furthermore, in this study we observed no differences in total
testosterone levels nor in FAI value across carriers of the various
genotypes. These results are consistent with previous studies. One in-
vestigation conducted in women from the UK showed no relationship
between FTO and androgen levels (Barber et al., 2008). A second study
conducted in a Polish population did not ﬁnd differences in testoster-
one, SHBG, and FAI between different genotypes (Kowalska et al.,
2009). Finally, a recent study on rs8050136 and two other polymor-
phisms showed no associationwith hyperandrogenemia after adjusting
for BMI (Song do et al., 2014). Only one study has reported higher free
testosterone in the presence of allele A of polymorphism rs9939609
(Wehr et al., 2010).
In the present study, both risk alleles for polymorphisms rs9939609
and rs8050136 were found to be associated with higher fasting glucose
levels. A previous study in patients with PCOS also found that impaired
fasting glucose was associated with the rs1421085 (C/T) polymorphism
in a Central European population, independently of BMI or age (Attaoua
et al., 2008). In addition, while few studies in patients with PCOS failed
to ﬁnd an association with glucose levels (Kowalska et al., 2012; Kim
et al., 2014; Song do et al., 2014), one study assessing the rs9939609
FTO variant and 10 metabolic traits using data from 17,037 white
European individuals revealed evidence for an association between FTO
genotype and fasting insulin, glucose, triglycerides, and HDL cholesterol
(Freathy et al., 2008). Recently, our group also conﬁrmed the association
between FTO genotypes and higher glucose levels inmenopausal women
(Ramos et al., 2011).
Regarding MetS, our study suggests that neither of the tested SNPs
nor any of the haplotypes of FTO aremajor risk factors for the syndrome,
conﬁrming a previous study in a population of 457 obese Caucasian
females (de Luis et al., 2013).
One limitation of this study was the relatively small sample size of
300 participants. However, the effect sizes observed in our sample are
similar to those reported in other PCOS populations. Moreover, in
order to control the possibility of stratiﬁcation bias by ethnicity, we
also analyzed only Caucasian subjects, thus reducing the risk of false
positive/negative associations due to this bias.
To date, there is no knownmechanism linking the FTO gene directly
to PCOS. In fact, studies in which an association was found between FTO
and PCOS susceptibility also observed an increase in adiposity, which
could be linked to a genetic interaction of the FTO gene with other sus-
ceptibility genes, combined to create the polygenic background of PCOS
(Kowalska et al., 2009). It is also important to point out that the studied
polymorphisms, which are located in intron 1, are in linkage disequilib-
rium, making it difﬁcult to discern the best single SNP surrogate to fully
capture genetic variability for this region.5. Conclusion
In conclusion, the present study was the ﬁrst to assess FTO gene var-
iants and PCOS susceptibility in Brazilian women. Our results indicated
that neither the FTO polymorphisms rs9939609 and rs8050136 nor its
haplotypes were related to PCOS, but suggest an association between
the presence of risk alleles of SNPs rs9939609 and rs8050136 and
fasting glucose levels in women from southern Brazil.Declaration of interest
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